CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,850,000 shares, a growth of 19.5% from the March 15th total of 4,060,000 shares. Based on an average trading volume of 812,400 shares, the short-interest ratio is presently 6.0 days. Currently, 5.2% of the company’s stock are sold short.

Institutional Investors Weigh In On CureVac

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its position in CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after acquiring an additional 4,425 shares during the period. Signaturefd LLC raised its holdings in shares of CureVac by 29.2% in the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company’s stock worth $123,000 after purchasing an additional 8,170 shares during the period. XTX Topco Ltd lifted its stake in CureVac by 90.2% in the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company’s stock valued at $83,000 after purchasing an additional 11,553 shares during the last quarter. Barclays PLC grew its holdings in CureVac by 51.8% during the fourth quarter. Barclays PLC now owns 34,836 shares of the company’s stock valued at $118,000 after purchasing an additional 11,890 shares during the period. Finally, Two Sigma Advisers LP purchased a new stake in CureVac in the fourth quarter worth $48,000. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Stock Down 0.6 %

CVAC opened at $3.19 on Wednesday. CureVac has a fifty-two week low of $2.22 and a fifty-two week high of $5.28. The firm has a market capitalization of $715.64 million, a P/E ratio of 5.80 and a beta of 2.48. The company’s 50-day moving average is $3.06 and its 200 day moving average is $3.17. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19.

CureVac (NASDAQ:CVAC) last released its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. Research analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities reiterated a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a report on Friday, February 14th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.